Daniel Payne

2 days ago | statnews.com | Daniel Payne |Ed Silverman

WASHINGTON — President Trump’s executive order to lower drug prices through sweeping, cross-agency action left leaders in the pharmaceutical industry scrambling Monday to make sense of what may be ahead — and how to respond. The announcement was long on messaging, but short on details. That may explain why share prices for many pharmaceutical and biotech companies dropped in the hours before the announcement, but gained ground after investors took stock of Trump’s moves.

5 days ago | statnews.com | John Wilkerson |Daniel Payne

WASHINGTON — President Trump is widely expected to try to advance a “most-favored nation” policy next week in an effort to reduce U.S. drug prices — a move that is likely to significantly rattle the pharmaceutical industry, cheer his political base, and, possibly, leave open some very big questions.

1 week ago | statnews.com | Daniel Payne |John Wilkerson

Some Republicans lawmakers are reopening the door to look for savings in Medicaid beyond waste, fraud, and abuse — but they’re hitting roadblocks. With a looming deadline from President Trump to find hundreds of billions of dollars in savings to fund tax cut extensions, some lawmakers are hinting at a potentially fraught approach to reducing Medicaid spending: rethinking who should be eligible in the first place.

1 week ago | statnews.com | Daniel Payne

WASHINGTON — President Trump on Friday proposed massive cuts to the federal government’s health agencies in his 2026 budget request, arguing that Congress should reduce spending by tens of billions from current levels. The request would be a 26% cut to the Department of Health and Human Services’ discretionary budget, which doesn’t include spending on health coverage programs like Medicare and Medicaid.

2 weeks ago | statnews.com | Daniel Payne

WASHINGTON — After November’s election, many of the lobbyists and lawyers representing the health care industry expected a second Trump term would be much like the first: opportunities for regulatory trims, concerns about budget cuts, and more governing via social media. But less than 100 days into President Trump’s administration, far more sweeping changes are materializing for the health care industry, creating unprecedented challenges for companies and their Washington lobbyists.